TaiAn Technologies
VC Fund
Taipei, Taiwan
TaiAn Technologies is a VC fund in Taipei focused on Biotechnology and Medical. TaiAn Technologies Corporation is a technology advisory company that specializes in commercializing intellectual properties in the life sciences. Our team comprised of numerous biomedical experts that work closely with investment professionals to support up-and-coming life science technologies. Most importantly, we are entrusted by our shareholdersto explore technology platforms in the life sciences arena, to build upon the novel technologies, and to transform them into viable business opportunities supporting existing or creating new entities. Our shareholders comprised of Development Fund of the Executive Yuan of Taiwan as well as numerous conglomerates that are recognized in Taiwan and internationally well known. Leveraging our shareholders/ partners' resources and our strong management team, our multiplex services create synergies with Taiwanese corporations and add significant value to your company.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries TaiAn Technologies invests in
Stages TaiAn Technologies invests in
Countries TaiAn Technologies invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Series A
- $7.6M–$23M
Investment Focus
Industry
- Biotechnology 6 (75%)
- Medical 5 (63%)
- Therapeutics 3 (38%)
- Health Diagnostics 2 (25%)
- Hospital 1 (13%)
Stage
- Series A 4 (50%)
- Series B 2 (25%)
- Seed 1 (13%)
- Series C 1 (13%)
Country
- Taiwan 6 (75%)
- United States 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Allen Leu
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
|
Amy Huang
VP and Managing Director
|
VP and Managing Director | Total investments: 0 | Find email | |
|
Catherine Tsai
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
|
Chester Ho
CEO
|
CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Primo Biotechnology
|
Primo Biotechnology harnesses advanced molecular imaging and radiopharmaceutical science to provide precise clinical information via targeted radiopharmaceuticals. Primo Biotechnology aims to form a patient-centric healthcare model and establish doctor-patient relationships founded on trust towards conveying hope and happiness to all patients. | $7.6M / Series A / Jul 02, 2025 | |
Elixiron Immunotherapeutics
|
Elixiron Immunotherapeutics is a company developing therapeutics for cancer, neurological diseases, and inflammatory disorders. | Series B / Jun 17, 2025 | |
AnBogen Therapeutics
|
Anbogen is a clinical-stage biotechnology company dedicated to developing precision anti-cancer drugs that hold the/promise of curing cancers and/or improving the lives of cancer patients worldwide. | $12.5M / Series A / Jan 31, 2024 | |
AnHorn Medicines
|
AnHorn Medicines is a drug discovery company that develops therapeutic medicines for cancer, neurodegeneration, and aging diseases. | $10M / Series A / Apr 25, 2023 | |
AcadeMab Biomedical
|
AcadeMab Biomedical focuses on antibody and mRNA vaccine development to treat human diseases and enhance human health and well-being. | Seed / Jan 01, 2022 | |
APRINOIA Therapeutics
|
APRINOIA is a late-stage biotechnology company committed to protecting patients' brain health and changing outcomes of neurodegenerative diseases through first-in-class and best-in-class diagnostic tools and novel therapies. The company aims to bring precision medicine to neuroscience by identifying and targeting the protein aggregates of tau,alpha-synuclein and other proteins that play a critical role in the pathogenesis of many neurodegenerative diseases, such as Alzheimer's and Parkinson's Diseases. The company currently has operations in Hong Kong, Suzhou, Shanghai, Tokyo, and Boston. | $40M / Series C / Dec 28, 2021 | |
|
APRINOIA Therapeutics
|
APRINOIA is a late-stage biotechnology company committed to protecting patients' brain health and changing outcomes of neurodegenerative diseases through first-in-class and best-in-class diagnostic tools and novel therapies. The company aims to bring precision medicine to neuroscience by identifying and targeting the protein aggregates of tau,alpha-synuclein and other proteins that play a critical role in the pathogenesis of many neurodegenerative diseases, such as Alzheimer's and Parkinson's Diseases. The company currently has operations in Hong Kong, Suzhou, Shanghai, Tokyo, and Boston. | $11.1M / Series B / Jan 16, 2018 | |
Sapience Therapeutics
|
Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Our drug development program involves translating science into novel therapies, and our initial goal is to develop a first-in-class treatment for glioblastoma multiforme(GBM), which is the most severe and deadly form of brain cancer.The company was founded in 2015 by Barry Kappel and is based in Scarsdale, New York, United States. | $22.5M / Series A / Jul 12, 2016 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does TaiAn Technologies invest in?
TaiAn Technologies invests primarily in Biotechnology, Medical and Therapeutics startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in Taiwan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is TaiAn Technologies's check size?
TaiAn Technologies typically joins rounds of $7.6M–$23M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds TaiAn Technologies participates in.
How do I contact TaiAn Technologies?
Public channels for TaiAn Technologies include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at TaiAn Technologies?
The team at TaiAn Technologies includes Allen Leu (Managing Director), Amy Huang (VP and Managing Director) and Catherine Tsai (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
